The trajectory of companies tied to Sildenafil's history presents a challenging investment picture . While the initial success generated substantial gains, generic copies have significantly eroded sales . Investing in associated pharmaceutical businesses now requires a thorough assessment of patent rights , evolving patient trends , and the possibi